Current Status and Future Treatment Options for Chronic Hepatitis B
| 시간 | 일정 | 비고 |
|---|---|---|
| 13:20 ~ 13:30 | 환영사 | 박능화 (부산-울산-경남지회 회장) |
| 격려사 | 이정일 (대한간학회 회장) | |
| Session 1 | Challenges for the current treatment options (Pros vs. Cons) | 좌장: 이정일, 조몽 |
| Discontinuing NUCs [nucleos(-t)ide] treatment before HBsAg loss | ||
| 13:30 ~ 13:45 | Pros: Discontinuing NUCs [nucleos(-t)ide] treatment before HBsAg loss | 윤기태 (부산의대) |
| 13:45 ~ 14:00 | Cons: Discontinuing NUCs [nucleos(-t)ide] treatment before HBsAg loss | 조현진 (경상의대) |
| Treating CHB patients in Immune-tolerance phase | ||
| 14:00 ~ 14:15 | Pros: Treating CHB patients in Immune-tolerance phase | 이정훈 (서울의대) |
| 14:15 ~ 14:30 | Cons: Treating CHB patients in Immune-tolerance phase | 장정원 (가톨릭의대) |
| Treating liver cirrhosis patients with low viral load | ||
| 14:30 ~ 14:45 | Pros: Treating liver cirrhosis patients with low viral load | 신동현 (성균관의대) |
| 14:45 ~ 15:00 | Cons: Treating liver cirrhosis patients with low viral load | 백양현 (동아의대) |
| 15:00 ~ 15:10 | Q & A | |
| 15:10 ~ 15:30 | Coffee break | |
| Session 2 | Roles of antiviral agents in the natural course of CHB | 좌장: 변관수, 박능화 |
| 15:30 ~ 15:50 | Prevention of vertical transmission with NUC : Indication and clinical practice | 허내윤 (인제의대) |
| 15:50 ~ 16:10 | Roles of Interferon in NUC era | 우현영 (부산의대) |
| 16:10 ~ 16:30 | Prediction models of HCC development in CHB | 김범경 (연세의대) |
| Session 3 | New treatment options for CHB | 좌장: 이상욱, 한상영 |
| 16:30 ~ 16:50 | Tenofovir alafenamide and besifovir | 이현웅 (중앙의대) |
| 16:50 ~ 17:10 | HBV entry inhibitors, HBV cccDNA inhibitors & others | 홍영미 (부산의대) |
| 17:10 ~ 17:30 | Therapeutic vaccine | 윤승규 (가톨릭의대) |
| 17:30 ~ 17:35 | Closing | 이한주 (대한간학회 총무이사) |
사전등록마감 : 2017년 02월 13일(월) 오후 16시까지
PC버전에서 등록 가능합니다.